Product Description
Maltodextrins (MDs) are a class of carbohydrates (CHOs) extracted from a range of botanical sources.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | France | Greece | Malaysia | Spain | Taiwan | United Arab Emirates | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: Nestle
Company Location: VEVEY V8
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Slovakia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Diarrhea|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MAOGIT | P3 |
Recruiting |
Other |
2025-01-01 |
66% |
| NCT02819960 | P3 |
Completed |
Diarrhea |
2022-08-01 |
67% |